Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 544

1.

Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.

Costa S, Scott DW, Steidl C, Peacock SJ, Regier DA.

Curr Oncol. 2019 Apr;26(2):108-113. doi: 10.3747/co.26.4565. Epub 2019 Apr 1.

2.

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.

Biccler JL, Savage KJ, Brown PDN, Jørgensen J, Larsen TS, Poulsen CB, Stoltenberg D, Sehn LH, Scott DW, Gerrie AS, Jakobsen LH, Bøgsted M, El-Galaly TC, Villa D.

Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594219. [Epub ahead of print]

PMID:
30943052
3.

Fabrication and mechanical characterization of 3D printed vertical uniform and gradient scaffolds for bone and osteochondral tissue engineering.

Bittner SM, Smith BT, Diaz-Gomez L, Hudgins CD, Melchiorri AJ, Scott DW, Fisher JP, Mikos AG.

Acta Biomater. 2019 May;90:37-48. doi: 10.1016/j.actbio.2019.03.041. Epub 2019 Mar 21.

PMID:
30905862
4.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Mar 14. doi: 10.1111/bjh.15860. [Epub ahead of print] No abstract available.

PMID:
30873584
5.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
6.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
7.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

PMID:
30523716
8.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

9.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

10.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

PMID:
30257882
11.

Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.

Parvathaneni K, Scott DW.

Blood Adv. 2018 Sep 25;2(18):2332-2340. doi: 10.1182/bloodadvances.2018018556.

12.

Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?

Scott DW, Rimsza LM.

Best Pract Res Clin Haematol. 2018 Sep;31(3):187-198. doi: 10.1016/j.beha.2018.07.003. Epub 2018 Jul 7. Review.

PMID:
30213388
13.

High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.

Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci B, Clissa C, Song K, Toze C, Abou Mourad Y, Sutherland H, Sanford D, Nantel SH, Sehn LH, Scott DW, Savage KJ, Connors JM, Gerrie AS, Isidori A.

Bone Marrow Transplant. 2019 Mar;54(3):481-484. doi: 10.1038/s41409-018-0328-9. Epub 2018 Aug 31. No abstract available.

PMID:
30171222
14.

SAMHD1 Posttranscriptionally Controls the Expression of Foxp3 and Helios in Human T Regulatory Cells.

Kim YC, Kim KK, Yoon J, Scott DW, Shevach EM.

J Immunol. 2018 Sep 15;201(6):1671-1680. doi: 10.4049/jimmunol.1800613. Epub 2018 Aug 13.

PMID:
30104243
15.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

PMID:
30095158
16.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

PMID:
30080252
17.

Incorporation of fast dissolving glucose porogens and poly(lactic-co-glycolic acid) microparticles within calcium phosphate cements for bone tissue regeneration.

Smith BT, Lu A, Watson E, Santoro M, Melchiorri AJ, Grosfeld EC, van den Beucken JJJP, Jansen JA, Scott DW, Fisher JP, Mikos AG.

Acta Biomater. 2018 Sep 15;78:341-350. doi: 10.1016/j.actbio.2018.07.054. Epub 2018 Aug 1.

PMID:
30075321
18.

Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.

Zhang AH, Yoon J, Kim YC, Scott DW.

J Immunol. 2018 Sep 1;201(5):1434-1441. doi: 10.4049/jimmunol.1701800. Epub 2018 Jul 18.

PMID:
30021767
19.

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.

Villa D, Sehn LH, Aquino-Parsons C, Tonseth P, Scott DW, Gerrie AS, Wilson D, Bénard F, Gascoyne RD, Slack GW, Farinha P, Morris J, Pickles T, Connors JM, Savage KJ.

Haematologica. 2018 Dec;103(12):e590-e593. doi: 10.3324/haematol.2018.196782. Epub 2018 Jul 12. No abstract available.

20.

SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum.

Sesma JI, Wu B, Stuhlmiller TJ, Scott DW.

J Cyst Fibros. 2019 Mar;18(2):244-250. doi: 10.1016/j.jcf.2018.06.002. Epub 2018 Jun 20.

21.

Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Kim YC, Zhang AH, Yoon J, Culp WE, Lees JR, Wucherpfennig KW, Scott DW.

J Autoimmun. 2018 Aug;92:77-86. doi: 10.1016/j.jaut.2018.05.003. Epub 2018 May 30.

PMID:
29857928
22.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.

PMID:
29769262
23.

Vinculin Force-Sensitive Dynamics at Focal Adhesions Enable Effective Directed Cell Migration.

Rothenberg KE, Scott DW, Christoforou N, Hoffman BD.

Biophys J. 2018 Apr 10;114(7):1680-1694. doi: 10.1016/j.bpj.2018.02.019.

24.

Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.

Sicard A, Levings MK, Scott DW.

Am J Transplant. 2018 Jun;18(6):1305-1311. doi: 10.1111/ajt.14747. Epub 2018 Apr 21. Review.

25.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR.

Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.

26.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

27.

FOXP3 renders activated human regulatory T cells resistant to restimulation-induced cell death by suppressing SAP expression.

Katz G, Voss K, Yan TF, Kim YC, Kortum RL, Scott DW, Snow AL.

Cell Immunol. 2018 May;327:54-61. doi: 10.1016/j.cellimm.2018.02.007. Epub 2018 Feb 12.

28.

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.

Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, Gascoyne RD, Mungall AJ, Marra MA, Scott DW, Connors JM, Steidl C.

J Mol Diagn. 2018 Mar;20(2):203-214. doi: 10.1016/j.jmoldx.2017.11.010. Epub 2018 Feb 8.

PMID:
29429887
29.

AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R.

Nat Commun. 2018 Jan 15;9(1):222. doi: 10.1038/s41467-017-02595-w.

30.

From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.

Scott DW.

Front Immunol. 2017 Nov 13;8:1576. doi: 10.3389/fimmu.2017.01576. eCollection 2017. Review.

31.

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Bosch M, Akhter A, Chen BE, Mansoor A, Lebrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA.

Haematologica. 2018 Feb;103(2):288-296. doi: 10.3324/haematol.2017.179309. Epub 2017 Nov 2.

32.

Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision.

Adair PR, Kim YC, Zhang AH, Yoon J, Scott DW.

Front Immunol. 2017 Sep 21;8:1117. doi: 10.3389/fimmu.2017.01117. eCollection 2017. Review.

33.

Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.

Terryah ST, Fellner RC, Ahmad S, Moore PJ, Reidel B, Sesma JI, Kim CS, Garland AL, Scott DW, Sabater JR, Carpenter J, Randell SH, Kesimer M, Abraham WM, Arendshorst WJ, Tarran R.

Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L192-L205. doi: 10.1152/ajplung.00546.2016. Epub 2017 Oct 5.

34.

Observation as the initial management strategy in patients with mantle cell lymphoma.

Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D.

Ann Oncol. 2017 Oct 1;28(10):2489-2495. doi: 10.1093/annonc/mdx333.

PMID:
28961827
35.

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.

Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C.

J Clin Oncol. 2017 Nov 10;35(32):3722-3733. doi: 10.1200/JCO.2017.72.7925. Epub 2017 Sep 12.

PMID:
28898161
36.

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.

Jais JP, Molina TJ, Ruminy P, Gentien D, Reyes C, Scott DW, Rimsza LM, Wright G, Gascoyne RD, Staudt LM, Haioun C, Tilly H, Gaulard P, Salles GA, Jardin F, Leroy K.

Haematologica. 2017 Oct;102(10):e404-e406. doi: 10.3324/haematol.2017.166827. Epub 2017 Jul 4. No abstract available.

37.

Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.

Parvathaneni K, Abdeladhim M, Pratt KP, Scott DW.

Transl Res. 2017 Sep;187:44-52. doi: 10.1016/j.trsl.2017.06.002. Epub 2017 Jun 9. Review.

38.

Automated high throughput nucleic acid purification from formalin-fixed paraffin-embedded tissue samples for next generation sequence analysis.

Haile S, Pandoh P, McDonald H, Corbett RD, Tsao P, Kirk H, MacLeod T, Jones M, Bilobram S, Brooks D, Smailus D, Steidl C, Scott DW, Bala M, Hirst M, Miller D, Moore RA, Mungall AJ, Coope RJ, Ma Y, Zhao Y, Holt RA, Jones SJ, Marra MA.

PLoS One. 2017 Jun 1;12(6):e0178706. doi: 10.1371/journal.pone.0178706. eCollection 2017.

39.

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphoma Study Group.

J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.

PMID:
28525305
40.

Synthesis and Characterization of Diol-Based Unsaturated Polyesters: Poly(diol fumarate) and Poly(diol fumarate-co-succinate).

Tatara AM, Watson E, Satish T, Scott DW, Kontoyiannis DP, Engel PS, Mikos AG.

Biomacromolecules. 2017 Jun 12;18(6):1724-1735. doi: 10.1021/acs.biomac.7b00044. Epub 2017 May 17.

PMID:
28486802
41.

SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.

Scott DW, Walker MP, Sesma J, Wu B, Stuhlmiller TJ, Sabater JR, Abraham WM, Crowder TM, Christensen DJ, Tarran R.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):734-744. doi: 10.1164/rccm.201612-2445OC.

PMID:
28481660
42.

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW.

Blood. 2017 May 18;129(20):2760-2770. doi: 10.1182/blood-2016-11-747022. Epub 2017 Mar 28.

43.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

44.

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.

Yoon J, Schmidt A, Zhang AH, Königs C, Kim YC, Scott DW.

Blood. 2017 Jan 12;129(2):238-245. doi: 10.1182/blood-2016-07-727834. Epub 2016 Nov 15.

45.

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.

Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP.

PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.

46.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

47.

Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.

Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M.

Virchows Arch. 2017 Jan;470(1):113-117. doi: 10.1007/s00428-016-2041-7. Epub 2016 Nov 25. No abstract available.

PMID:
27888357
48.

A time-and-motion approach to micro-costing of high-throughput genomic assays.

Costa S, Regier DA, Meissner B, Cromwell I, Ben-Neriah S, Chavez E, Hung S, Steidl C, Scott DW, Marra MA, Peacock SJ, Connors JM.

Curr Oncol. 2016 Oct;23(5):304-313. Epub 2016 Oct 25.

49.

Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience.

Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ.

Br J Haematol. 2017 Jan;176(2):234-240. doi: 10.1111/bjh.14404. Epub 2016 Oct 21.

PMID:
27766622
50.

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.

Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM.

Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12.

Supplemental Content

Loading ...
Support Center